Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

bioAffinity Technologies (BIAF) Gross Margin (2022 - 2025)

Historic Gross Margin for bioAffinity Technologies (BIAF) over the last 4 years, with Q3 2025 value amounting to 34.84%.

  • bioAffinity Technologies' Gross Margin fell 38800.0% to 34.84% in Q3 2025 from the same period last year, while for Sep 2025 it was 27.86%, marking a year-over-year decrease of 71700.0%. This contributed to the annual value of 36.09% for FY2024, which is 48300.0% up from last year.
  • Latest data reveals that bioAffinity Technologies reported Gross Margin of 34.84% as of Q3 2025, which was down 38800.0% from 19.92% recorded in Q2 2025.
  • Over the past 5 years, bioAffinity Technologies' Gross Margin peaked at 93.75% during Q2 2023, and registered a low of 19.92% during Q2 2025.
  • In the last 4 years, bioAffinity Technologies' Gross Margin had a median value of 40.01% in 2024 and averaged 55.54%.
  • Within the past 5 years, the most significant YoY rise in bioAffinity Technologies' Gross Margin was 49300bps (2023), while the steepest drop was -677600bps (2023).
  • Over the past 4 years, bioAffinity Technologies' Gross Margin (Quarter) stood at 92.54% in 2022, then crashed by -73bps to 24.78% in 2023, then rose by 18bps to 29.24% in 2024, then rose by 19bps to 34.84% in 2025.
  • Its last three reported values are 34.84% in Q3 2025, 19.92% for Q2 2025, and 26.21% during Q1 2025.